SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs stronger-than-expected quarterly results and rapid growth in its AI/compute business are driving attention, with traders cheering the shift toward AI and the companys growth outlook. Others question the valuation and heavy spending, while discussion of a possible Tesla merger remains speculative, with no deal agreed.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix shares are under pressure after its quarterly report paired an earnings beat with softer-than-expected fourth-quarter guidance and a reduced advertising outlook, reinforcing concerns about slowing growth. Traders are split between viewing the selloff as a buying opportunity given the companys profitability and buybacks, and expecting further weakness amid competition and doubts about future growth.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary quarterly update sharply raised its revenue outlook on stronger AI-platform demand and lifted its gross-margin forecast, triggering a rally and bullish talk of a short squeeze. Traders welcomed the stronger figures but some remain cautious about execution, cash flow, and whether the full results will confirm the update.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE is selling off despite beating quarterly estimates and raising its outlook, as traders focus on cost pressures, weaker cash conversion, and supply-chain constraints. The community is split between dip buyers citing strong demand and backlog and skeptics pointing to repeated post-earnings declines and concerns about whether growth will translate into returns.

Corning, Inc. engages in the provision of glass for notebook computers, flat panel desktop monitors, display televisions, and other information display applications, carrier network and enterprise network products for the telecommunications industry, ceramic substrates for gasoline and diesel engines in automotive and heavy-duty vehicle markets, laboratory products for the scientific community and polymer products for biotechnology applications, optical materials for the semiconductor industry and the scientific community, and polycrystalline silicon products and other technologies. It operates through the following segments: Optical Communications, Display, Specialty Materials, Automotive, and Life Sciences. The Optical Communications segment is classified into two main product groupings: carrier and enterprise network. The carrier network group consists of products and solutions for optical-based communications infrastructure for services such as video, data, and voice communications. The enterprise network group consists primarily of optical-based communication networks sold to businesses, governments, and individuals for their own use. The Display Technologies segment manufactures glass substrates for flat panel displays, including organic light-emitting diodes and liquid crystal displays that are used primarily in televisions, notebook computers, desktop monitors, tablets, and handheld devices. The Specialty Materials segment is involved in the manufacture of products that provide material formulations for glass, glass ceramics and crystals, and precision metrology instruments and software. The Automotive segment manufactures ceramic substrates and filter products for emissions control in mobile applications around the world as well as technical glass and optic products and solutions for the interior and exterior of vehicles. The Life Sciences segment develops, manufactures, and supplies laboratory products. The company was founded by Amory Houghton Sr. in 1851 and is headquartered in Corning, NY.

Corning, Inc.

Cornings announced at-the-market share-sale program has fueled dilution concerns and a sharp, volatile pullback. Bulls counter that the financing can support capacity expansion and that AI data-center connectivity demand and large fiber-supply agreements underpin the longer-term case.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disneys recent rebound and attempt to clear technical resistance are drawing attention, with traders positioning for further gains ahead of its scheduled earnings report. Bullish call activity and optimism about the recovery are countered by skepticism that the stock can sustain its move after years of weak performance.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

CEO Paul Pragers comments reaffirming strong demand for future power capacity and progress on TeraWulfs AI data-center buildout have fueled renewed interest, with traders also emphasizing the companys power-and-hosting model versus GPU-owning neoclouds. The sharp rebound has drawn bullish calls that the selloff was overdone, while skeptics question whether financing, delivery, and follow-through will support a lasting recovery.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart is drawing attention amid a prolonged selloff and concerns about its debt, funding needs, and sensitivity to elevated rates and credit conditions. Bulls point to the CEOs share purchase, improving originations, and bank-charter prospects, while many traders remain skeptical and debate whether high short interest could amplify a rebound.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

The CHMP upheld its negative opinion on Omeros European marketing application for YARTEMLEA, prompting concern about the lost EU opportunity and a selloff. Some traders view the reaction as an overreaction and point to U.S. launch demand and upcoming sales results as the key test, while others remain wary about whether U.S. growth can offset the setback.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Positive clinical data for Kyvernas miv-cel in stiff person syndrome and generalized myasthenia gravis, alongside progress toward an SPS BLA, is driving attention. Traders are weighing the therapys durability and safety against a sharp, volatile post-data reaction, with some attributing the pullback to profit-taking and potential dilution concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zacks.com featured highlights include AIM ImmunoTech, Hasbro, Fox, Cencora and Intuitive Surgical 

AIM, HAS, FOX, COR and ISRG make the list of stocks with rising P/E ratios, a screen highlighting companies investors may view as having stronger earnings potential.

Bet on 5 Top-Ranked Stocks With Rising P/E 

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. 

Bet on 5 Top-Ranked Stocks With Rising P/E for Solid Returns

Rising P/E ratios can signal confidence and momentum. Discover 5 stocks backed by strong earnings growth and upside potential.

FDA Milestones Fueling Expansion

The biotechnology sector delivered several notable developments. $TNGX, $NTHI, $AIM, $AZN, $NRIX, $NYXH

AIM Stock Soars Over 200% As Pancreatic Cancer Trial Hits Enrollment Milestone Early — CEO Sees 'Value-Inflection Period' Ahead

Equity

AIM ImmunoTech CEO Thomas K. Equels stated that the company is on track to complete the dosing of Ampligen.

Biodefense Spotlight Sends Microcap Soaring

As global health agencies monitor emerging infectious disease threats, interest can return quickly to legacy therapeutic platforms with broad antiviral potential. In biotech, especially among smaller names, previously published research can suddenly become highly relevant when the right real-world catalyst emerges. Shares of AIM ImmunoTech Inc. (NYSE American: AIM) are ripping higher in Tuesday trading, climbing after the company highlighted previously published pre-clinical data supporting the potential use of its lead drug candidate, Ampligen, as a prophylactic or early-intervention ...

Why Did AIM Stock Plummet 35% Today?

AIM ImmunoTech announced an agreement with certain accredited investors to exercise outstanding warrants for $0.48 per share to raise $4.2 million in gross proceeds.

Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum

Today’s action highlights biotech and healthcare innovators advancing novel therapies and strategic platforms amid rising demand for targeted treatments and efficient global access. With the biologics market surging toward $650 billion+ by 2030 and medical tourism accelerating, today's developments showcase capital-efficient clinical progress, high-growth partnerships, and operational scaling, creating compelling narratives in precision medicine, oncology adjuvants, and AI-enabled workforce solutions. $ARTL, $TGNT, $AIM, $YYGH

Why Did AIM Stock Jump 60% Today?

The company said that a patent using its proprietary cancer treatment method was fully approved in Japan.

This account has been verified as an official AIM representative.

Verified Account

AIM_ImmunoTech

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

AIM ImmunoTech Inc

Bullish Sentiment

<ul class="summary-bullets"><li>The enrollment milestone also marks progress in AIM ImmunoTech's broader strategy to advance Ampligen toward late-stage development in pancreatic cancer.</li><li>The company said it is continuing Phase 3 trial planning while expanding its global regulatory and intellectual property footprint.</li><li>AIM ImmunoTech said the planned Phase 3 program is backed by data from a Dutch Named Patient Program and encouraging results from the ongoing DURIPANC study.</li></ul><p>Shares of AIM ImmunoTech Inc. (AIM) soared&nbsp;more than 200% in Monday morning’s trade after the company announced that its pancreatic cancer trial hit a key enrollment milestone ahead of schedule.</p><p>AIM ImmunoTech announced final patient enrollment in its Phase 2 study of Ampligen (rintatolimod) combined with AstraZeneca's Imfinzi (durvalumab) for metastatic pancreatic cancer following FOLFIRINOX treatment.</p><p><a href="https://stocktwits.com/symbol/AIM">AIM ImmunoTech shares</a> were up more than 130% in Monday morning’s trade after paring some of the gains.</p><h2 class="st-heading-2">AIM CEO Says Ampligen Dosing On Track For Completion</h2><p>AIM ImmunoTech CEO Thomas K. Equels stated that the company is on track to complete the dosing of Ampligen, which should allow the company to evaluate the study's critical primary endpoint of Clinical Benefit Rate (CBR) in December 2026.</p><p>CBR measures the percentage of patients who achieve stable disease, a partial response or a complete response six months after starting the combination therapy.</p><p>“Together with our ongoing Phase 3 planning efforts, orphan drug designations in the United States and Europe, expanding global intellectual property portfolio, and growing body of positive clinical data, we believe Ampligen is advancing toward a significant value-inflection period for AIM,” Equels said.</p><h2 class="st-heading-2">AIM Advances Toward Phase 3 Development</h2><p>The enrollment milestone also marks progress in AIM ImmunoTech's broader strategy to advance Ampligen toward late-stage development in pancreatic cancer.</p><p>The company said it is continuing Phase 3 trial planning while expanding its global regulatory and intellectual property footprint. AIM added that the planned Phase 3 program is supported by previously published data from a Dutch government-approved Named Patient Program, as well as encouraging results from the ongoing DURIPANC study.</p><p>According to the company, more than 100 pancreatic cancer patients have been treated with Ampligen across these programs, helping the company acquire clinical experience to support the therapy's further development.</p><h2 class="st-heading-2">AIM’s Ampligen Ebola Presentation Due This Week</h2><p>AIM ImmunoTech announced last week that it plans to release an on-demand presentation highlighting previously published preclinical data supporting the potential use of Ampligen as both a preventive and early-stage antiviral treatment for Ebola virus disease.</p><p>The announcement comes amid rising concern over a Bundibugyo-strain Ebola outbreak in Central and East Africa, a variant that currently has no approved treatment or vaccine.</p><p>The company said research conducted at USAMRIID's Biosafety Level 4 laboratories demonstrated Ampligen's potential to address this unmet medical need.</p><h2 class="st-heading-2">How Did Retail Investors React To AIM Stock?</h2><p>Retail sentiment on Stocktwits around AIM ImmunoTech trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.</p><p><a href="https://stocktwits.com/symbol/AIM">AIM stock</a> is down 14% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/AZN">AZN stock</a> is down 2%. The Vanguard Extended Market Index Fund ETF (VXF) is up 29% over the past 12 months.</p><p>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/smci-stock-price-target-hike-agentic-ai-nvidia-jensen-huang-computex/cZ0gthCReHY"><strong>SMCI Stock Gets Target Boost As Mizuho Cites Agentic AI Demand — Jensen Huang Says 'One Prompt Can Launch A Thousand-Step Journey'</strong></a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Shares of REalloys Inc. surged on Monday (Representative image: Getty Images)

Shares of AIM ImmunoTech Inc. (AIM) soared nearly 42% in Monday’s opening trade after the company announced that its pancreatic cancer trial hit a key enrollment milestone ahead of schedule.

AIM Stock Soars 42% As Pancreatic Cancer Trial Hits Key Enrollment Milestone Before Schedule — CEO Sees 'Significant Value-Inflection Period' Ahead

AIM ImmunoTech

AstraZeneca PLC

Vanguard Extended Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.1662
Prev Close	$0.1631
Open	$0.1633
Dividend Yield	0.00%
50-Day Moving Average	$0.2129
Beta	0.42
Avg. Volume	6.23M
PE Ratio	-0.04

52-Week High	$2.88
52-Week Low	$0.1599
Market Capitalization	$6.51M
EPS (Annual)	-$8.61
Price to Book	0.62
Revenue Per Employee	$4,631.58

Feed

News

Sentiment

Fundamentals

Info

AIM Fundamentals